Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents (Q48616675)

13 February 2018

title

Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents (English)

1 reference

13 February 2018

1 reference

Tetsuhiro Tanaka

1

1 reference

13 February 2018

Masaomi Nangaku

series ordinal

2

1 reference

13 February 2018

language of work or name

English

0 references

publication date

6 March 2012

1 reference

13 February 2018

Experimental Cell Research

published in

1 reference

13 February 2018

volume

318

1 reference

13 February 2018

issue

9

1 reference

13 February 2018

page(s)

1068-1073

1 reference

13 February 2018

Identification of the renal erythropoietin-producing cells using transgenic mice

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

Human erythropoietin gene expression in transgenic mice: multiple transcription initiation sites and cis-acting regulatory elements

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

Cell-type-specific and hypoxia-inducible expression of the human erythropoietin gene in transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

Repression via the GATA box is essential for tissue-specific erythropoietin gene expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

Oxygen-regulated expression of the erythropoietin gene in the human renal cell line REPC.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

HIF-2alpha regulates murine hematopoietic development in an erythropoietin-dependent manner

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

A gain-of-function mutation in the HIF2A gene in familial erythrocytosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

Indoxyl sulfate, a representative uremic toxin, suppresses erythropoietin production in a HIF-dependent manner

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

Anti-Epo receptor antibodies do not predict Epo receptor expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

Erythropoietin therapy for acute stroke is both safe and beneficial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

Recombinant human erythropoietin in the treatment of acute ischemic stroke

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

A novel protective effect of erythropoietin in the infarcted heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

Derivatives of erythropoietin that are tissue protective but not erythropoietic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

A "classical" homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

A nonerythropoietic peptide that mimics the 3D structure of erythropoietin reduces organ injury/dysfunction and inflammation in experimental hemorrhagic shock.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

Erythropoietin protects against ischaemic acute renal injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

Renoprotective effect of erythropoietin against ischaemia-reperfusion injury in a non-human primate model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

The continuous erythropoietin receptor activator affects different pathways of diabetic renal injury.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

Darbepoetin alfa protects podocytes from apoptosis in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

Erythropoietin induces heme oxygenase-1 expression and attenuates oxidative stress.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

Correction of anemia with epoetin alfa in chronic kidney disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.035

10.1016/J.YEXCR.2012.02.035

7 January 2021

Identifiers

DOI

1 reference

13 February 2018

1 reference

13 February 2018